The SUPPORT for Patients and Communities Reauthorization Act of 2025 reauthorizes multiple federal programs that prevent, treat, and support recovery from substance use disorders and adds new programmatic authorities, reporting requirements, and funding levels for fiscal years 2026–2030. The bill creates a dedicated federal program for fetal alcohol spectrum disorder (FASD) prevention and services, increases appropriations for a range of prevention and recovery activities, and expands the scope of surveillance and education efforts to include emerging substances and associated risk factors.
Beyond funding updates, the statute imposes several operational and oversight duties: HHS must publish an FDA-focused assessment of approved opioid analgesics, convene a health IT roundtable targeting behavioral health EHR adoption, and implement cybersecurity reporting and protections for the 9‑8‑8 National Suicide Prevention Lifeline. The measure also directs interagency and program-level reviews (including a GAO study) and clarifies state discretion over PDMP vendor and interoperability choices.
At a Glance
What It Does
The bill authorizes specific funding levels for 2026–2030 across prevention, treatment, and recovery programs; establishes a new FASD prevention and services part with grant authority; broadens surveillance language to include ‘associated risks’ and emerging substances; and requires several reports, studies, and rule‑review processes by HHS, FDA, and the Attorney General.
Who It Affects
Federal grant recipients (States, Tribes, nonprofits, academic centers), public health surveillance systems, behavioral health and addiction treatment providers, pharmacies and prescribers, and entities operating the 9‑8‑8 lifeline. It also targets patients and family members affected by opioid use disorder and by FASD.
Why It Matters
It shifts programmatic emphasis toward broader surveillance (including wastewater as an allowable method), creates a permanent federal FASD grant structure, and ties several HHS processes to statutory deadlines—changes that will shape how states, providers, and grantees prioritize prevention, clinical care, and technical infrastructure over the next funding cycle.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The statute refreshes and extends many SUPPORT Act-era programs and inserts new programmatic authorities. Appropriations language updates authorize multi‑year funding for prevention, treatment, and recovery activities for fiscal years 2026–2030 and, in one major structural change, establishes Part O in title III of the Public Health Service Act to create a coordinated FASD prevention, intervention, and services delivery program.
That new part authorizes grants, technical assistance, and an applied research stream; eligible grantees include States, Tribes, local governments, academic institutions, and nonprofits.
On surveillance and prevention, the bill broadens existing language to replace references to ‘‘opioids’’ with ‘‘substances causing overdose’’ and inserts ‘‘associated risks’’ repeatedly, allowing grantees to detect and respond to changing patterns of substance use. It explicitly permits innovative tools—such as wastewater surveillance—if they support actionable prevention strategies and comply with applicable privacy laws.
The measure also preserves State choice in prescription drug monitoring program (PDMP) vendor and interoperability decisions by prohibiting HHS from mandating a specific vendor or connection outside alignment with consensus-based open standards.Treatment and workforce provisions strengthen access to addiction medicine through training, loan repayment increases for the SUD workforce, and tweaks to residential treatment program applications (including outreach plans targeted at disproportionately affected women). The bill also directs the FDA to publish within one year a plan assessing approved opioid analgesics’ public‑health effects and timelines for potential label changes or post‑market actions, and it requires HHS to review scheduling for products that combine buprenorphine and naloxone and, if warranted, request DOJ rulemaking.Recovery and systems supports receive fresh attention: funding boosts for peer support centers and community recovery programs, optional regional technical assistance centers, and an expanded CAREER Act that ties grant eligibility and outcomes to labor market metrics from 2018–2022.
Finally, the legislation adds operational requirements: mandatory cybersecurity vulnerability and incident reporting and a GAO study for the 9‑8‑8 lifeline, guidance on at‑home drug disposal systems, and a public roundtable to explore electronic health record adoption and certification issues for mental health and substance use providers.
The Five Things You Need to Know
Section 392A receives $505,579,000 authorized for each fiscal year 2026–2030 to support detection and rapid response to controlled substance misuse and overdoses, including funding for innovative surveillance methods where lawful and actionable.
The bill creates Part O for FASD prevention and services and authorizes $12,500,000 per year for fiscal years 2026–2030 for education, screening capacity, research, and grants to States, Tribes, local governments, academic institutions, and nonprofits.
The 9‑8‑8 National Suicide Prevention Lifeline must implement cybersecurity protections and local/regional crisis centers and network administrators must report identified vulnerabilities and incidents to the Assistant Secretary; the Comptroller General must complete a GAO study on 9‑8‑8 cybersecurity risks within 180 days.
HHS must publish on the FDA website within one year a report and plan assessing approved opioid analgesic drugs’ public‑health effects, including timelines for labeling changes, post‑market requirements, enforcement, or withdrawals and public input opportunities.
The Secretary of HHS must review the scheduling data for FDA‑approved buprenorphine–naloxone combination products and may request the Attorney General to initiate Controlled Substances Act scheduling rulemaking based on that review.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Prevention suite: funding, surveillance, and FASD program
This title updates authorization levels for multiple prevention programs and broadens the statutory surveillance remit: it replaces repeated ‘‘opioid’’ language with ‘‘substances causing overdose’’ and inserts ‘‘associated risks,’’ allowing grants to target emerging substances and risk factor monitoring. The centerpiece is creating Part O for FASD prevention, which establishes grantmaking, technical assistance, and an applied research agenda, including requirements for eligible entities to apply and optionally designate a State/Tribal FASD coordinator. Practically, the title opens channels for novel surveillance (for example, wastewater) but ties use to privacy law compliance, and it preserves state discretion over PDMP vendor choice by directing alignment with open standards rather than single‑vendor mandates.
First responder training and 9‑8‑8 cybersecurity/reporting
Section 106 expands the scope and eligible technologies in first responder training grants by removing ‘‘opioid‑only’’ limitations and allowing legally marketed devices and drugs beyond those formally FDA‑approved or cleared. Section 108 mandates specific cybersecurity protections for the 9‑8‑8 lifeline, creates a multilayered reporting regime (local centers to network administrators to the Assistant Secretary), and requires a GAO study on lifeline cybersecurity within 180 days—adding concrete oversight and reporting responsibilities for both grantees and network operators.
Treatment, workforce, FDA assessment, and health IT for behavioral health
This title raises loan repayment and program funding for the SUD workforce and refines program application requirements for residential treatment programs serving pregnant and postpartum women. It charges FDA (via HHS) with producing a public plan within one year assessing opioid analgesics’ public‑health implications and potential regulatory actions, and it establishes a statutory process for HHS to review the scheduling status of buprenorphine–naloxone products and, if warranted, ask the Attorney General to initiate scheduling proceedings. The National Coordinator for Health IT must convene a roundtable on EHR adoption in mental health and SUD settings and report findings to Congress—an explicit push to address behavioral‑health data interoperability and certification gaps.
Recovery and workforce reintegration programs
Title III ups funding for recovery community services and peer support technical assistance, authorizes a regional technical assistance center pilot with a four‑year evaluation, and retools the CAREER Act to tie grant formulas to 2018–2022 overdose, unemployment, and labor‑force metrics. The CAREER amendments also permit a small portion (up to 5 percent) of grant funds for transportation to enable participation in work or training and require reporting on employment and earnings outcomes, linking recovery services to measurable workforce outcomes.
Controlled substances delivery and prescriber training updates
The bill narrows and clarifies pharmacy delivery provisions for controlled substances used in maintenance or detoxification (or subject to REMS monitoring), and it expands the list of accrediting organizations recognized for prescriber training across medicine, dentistry, podiatry, nursing, and pharmacy. The prescriber training amendments are effective retroactively to December 29, 2022, which affects current accreditation pathways and educational requirements for controlled‑substance dispensing and prescribing.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals with or at risk of substance use disorders and their families — will see expanded prevention, treatment, and recovery grant funding, new FASD services, and more peer‑support resources funded at higher levels.
- State, Tribal, and local public health systems — gain statutory permission to deploy new surveillance tools (including wastewater where lawful), additional grant streams for FASD and recovery programming, and clearer PDMP vendor choice protections.
- Behavioral health and addiction workforce — receive increased loan repayment funding, training initiatives, and technical assistance that aim to expand provider capacity and addiction medicine access.
Who Bears the Cost
- HHS (and SAMHSA/FDA components) — must absorb added administrative duties: new reports, a GAO study response, cybersecurity oversight, roundtable convenings, and the FDA opioid assessment within statutory deadlines without dedicated administrative offsets.
- Network administrators and local/regional 9‑8‑8 crisis centers — must implement cybersecurity protections and comply with vulnerability/incident reporting channels, potentially requiring technical upgrades and legal review to align with privacy obligations.
- Healthcare providers, accrediting bodies, and pharmacies — face expanded training requirements, documentation expectations for grant applications and recovery center referrals, and updated compliance for controlled‑substance delivery rules, which may require operational changes and additional staff training.
Key Issues
The Core Tension
The central dilemma is weighing expanded surveillance, tighter oversight, and stricter technical controls against patient access, privacy, and service capacity: the bill pushes federal and local systems to detect and respond to rapidly changing drug threats and to harden critical lifeline infrastructure, but doing so requires intrusive data practices, new reporting chains, and administrative capacity that can unintentionally reduce access to care or slow service delivery if not matched with sufficient funding and clear privacy guardrails.
The bill combines modest funding increases with several new procedural and oversight requirements that will drive implementation choices. Authorizations are stated as fixed annual amounts for 2026–2030 (for example, an increase to $505.6 million for the surveillance/grant line under section 392A and $12.5 million annually for the new FASD part), but authorization does not itself appropriate funds; actual budget execution will determine program growth.
Agencies must sequence multiple deliverables—FDA’s opioid assessment, HHS scheduling review of buprenorphine–naloxone, GAO cybersecurity work, and an HHS roundtable on health IT—into overlapping timelines that could strain staff capacity unless Congress supplies incremental appropriations for administrative implementation.
The bill authorizes innovative surveillance approaches, explicitly naming wastewater surveillance as permissible if it supports ‘‘actionable prevention strategies’’ and complies with privacy laws. That approach creates a practical tension: wastewater and other population‑level tools offer early signals, but privacy, consent, and data‑use constraints will limit what states and grantees can operationalize.
Similarly, the cybersecurity reporting chain for 9‑8‑8 seeks rapid notification of vulnerabilities, but it leaves open how much technical oversight the federally funded network administrator may exercise over independent local centers—a gap that will surface in network participation agreements and may require further contractual standardization or policy guidance.
Finally, the statutory instruction for HHS to review the scheduling of buprenorphine–naloxone products places scientific review next to regulatory action that can affect access. Any recommendation to tighten or loosen schedules implicates treatment access, diversion risk, and criminal justice concerns; the statute preserves the formal CSA criteria and Attorney General rulemaking, but it creates an expedited political and administrative pathway for scheduling reconsideration without prescribing how public‑health tradeoffs should be weighed operationally.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.